John J. Tentler

Medicine, University of Colorado Denver Anschutz Medical Campus

Affiliated withUniversity of Colorado Denver Anschutz Medical Campus

Research Area

Biography

John J. Tentler has not added Biography.
If you are John J. Tentler and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 23	2016

Other Publications

Article	Year
Selective repression of rat prolactin gene by stable expression of dominant-negative Ets in GH4 pituitary cells. Endocrine\| PubMed ID: 12668863	2003
The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. DNA and cell biology\| PubMed ID: 12713734	2003
ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene\| PubMed ID: 14767472	2004
Structural and functional analysis of the differential effects of c-Jun and v-Jun on prolactin gene expression. Molecular endocrinology (Baltimore, Md.)\| PubMed ID: 15231872	2004
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Molecular cancer therapeutics\| PubMed ID: 19174560	2009
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Molecular cancer therapeutics\| PubMed ID: 19755510	2009
Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20406842	2010
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20530704	2010
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Molecular cancer therapeutics\| PubMed ID: 20923857	2010
The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer model... Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20943761	2010
Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism. Molecular cancer\| PubMed ID: 21871131	2011
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22173548	2012
Patient-derived tumour xenografts as models for oncology drug development. Nature reviews. Clinical oncology\| PubMed ID: 22508028	2012
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nature chemical biology\| PubMed ID: 22660439	2012
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23136197	2013
CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1. The Journal of investigative dermatology\| PubMed ID: 23303449	2013
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 23358974	2013
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Frontiers in pharmacology\| PubMed ID: 23543898	2013
MERTK receptor tyrosine kinase is a therapeutic target in melanoma. The Journal of clinical investigation\| PubMed ID: 23585477	2013
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23757356	2013
Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24045180	2013
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Therapeutic advances in medical oncology\| PubMed ID: 24790649	2014
Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. Molecular cancer therapeutics\| PubMed ID: 25376610	2015
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PloS one\| PubMed ID: 25401499	2014
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Molecular cancer therapeutics\| PubMed ID: 25758253	2015
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Frontiers in pharmacology\| PubMed ID: 26136684	2015
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. Oncotarget\| PubMed ID: 26439693	2015
An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. BMC genomics\| PubMed ID: 26681397	2015
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget\| PubMed ID: 27385211	2016